| SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection P Feuerstadt, TJ Louie, B Lashner, EEL Wang, L Diao, JA Bryant, M Sims, ... New England Journal of Medicine 386 (3), 220-229, 2022 | 120 | 2022 |
| Changes in vaginal community state types reflect major shifts in the microbiome JP Brooks, GA Buck, G Chen, L Diao, DJ Edwards, JM Fettweis, ... Microbial ecology in health and disease 28 (1), 1303265, 2017 | 79 | 2017 |
| A phase 1b safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis MR Henn, EJ O’Brien, L Diao, BG Feagan, WJ Sandborn, C Huttenhower, ... Gastroenterology 160 (1), 115-127. e30, 2021 | 48 | 2021 |
| Sporulation genes associated with sporulation efficiency in natural isolates of yeast P Tomar, A Bhatia, S Ramdas, L Diao, G Bhanot, H Sinha PLoS One 8 (7), e69765, 2013 | 30 | 2013 |
| Local Ancestry Corrects for Population Structure in Saccharomyces cerevisiae Genome-Wide Association Studies L Diao, KC Chen Genetics 192 (4), 1503-1511, 2012 | 27 | 2012 |
| MixMir: microRNA motif discovery from gene expression data using mixed linear models L Diao, A Marcais, S Norton, KC Chen Nucleic acids research 42 (17), e135-e135, 2014 | 22 | 2014 |
| Multiple roles of PIWIL1 in mouse neocorticogenesis B Viljetic, L Diao, J Liu, Z Krsnik, SHR Wijeratne, R Kristopovich, ... bioRxiv, 106070, 2017 | 8 | 2017 |
| P421 SER-287, an investigational microbiome therapeutic, induces remission and endoscopic improvement in a placebo-controlled, double-blind randomised trial in patients with … B Misra, J Curran, H Herfarth, K Jagarlamudi, C Oneto, BR Bhandari, ... Journal of Crohn's and Colitis 12 (supplement_1), S317-S317, 2018 | 6 | 2018 |
| 85-Ser-287, an investigational Microbiome therapeutic, induces remission and endoscopic improvement in a Placebo-controlled, Double-Blind randomized trial in Patients with … M Bharat, J Curran, HH Herfarth, K Jagarlamudi, C Oneto, BR Bhandari, ... Gastroenterology (New York, NY 1943) 154 (6), S-25-S-25, 2018 | 6 | 2018 |
| The shuffle index and evaluation of models of signal transduction pathways EE Allen, L Diao, JS Fetrow, DJ John, RF Loeser, LB Poole Proceedings of the 45th annual southeast regional conference, 250-255, 2007 | 6 | 2007 |
| 623–Ser-287, an investigational microbiome therapeutic, induces widespread transcriptional changes related to clinical remission in a placebo-controlled, double-blind … L Diao, MC Nnamani, E OBrien, C Desjardins, A Martinez, S Simmons, ... Gastroenterology 156 (6), S-130, 2019 | 5 | 2019 |
| 1641. Treatment of Recurrent Clostridium difficile Infection With SER-109 Reduces Gastrointestinal Carriage of Antimicrobial Resistance Genes C Ford, M Henn, J Bryant, L Diao, J Wortman, A Tomlinson, K Litcofsky, ... Open Forum Infectious Diseases 5 (suppl_1), S46-S47, 2018 | 5 | 2018 |
| Tu2019-Engraftment of Ser-287, an Investigational Microbiome Therapeutic, is Related to Clinical Remission in a Placebo-Controlled, Double-Blind Randomized Trial (Seres-101) in … S Simmons, L Diao, E O'Brien, M Chafee, J Zhao, P Bernardo, D Cook, ... Gastroenterology 154 (6), S-1371-S-1372, 2018 | 4 | 2018 |
| LB15. SER-109, an Investigational Microbiome Therapeutic, Reduces Abundance of Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides Difficile Infection … TJ Straub, L Diao, C Ford, M Sims, TJ Louie, C Berenson, CS Kraft, ... Open Forum Infectious Diseases 8 (Supplement_1), S812-S813, 2021 | 2 | 2021 |
| Designed bacterial compositions and uses thereof A Martinez, EJ O'brien, SL Simmons, D Cook, MR Henn, ... US Patent App. 17/058,351, 2021 | 2 | 2021 |
| Rapid conversion of primary to secondary bile acids in subjects with recurrent Clostridioides difficile infection (CDI) following SER-109, an investigational microbiome therapeutic JA Bryant, L Diao, EJ O’Brien, CB Ford, KD Litcofsky, JR Wortman, ... Digestive Disease Week, virtual, May, 21-23, 2021 | 2 | 2021 |
| Statistical Modeling in Biomedical Research Y Zhao, DGD Chen Springer International Publishing, 2020 | 2 | 2020 |
| 621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner M Henn, C Ford, E O’Brien, J Wortman, L Diao, C Desjardins, ... Open Forum Infectious Diseases 5 (suppl_1), S226-S227, 2018 | 2 | 2018 |
| Gastrointestinal tract microbiome dynamics following treatment with SER-109, an investigational oral microbiome therapeutic to reduce the recurrence of Clostridium difficile … M Henn, C Ford, E O’Brien, J Wortman, S Simmons, L Diao, K Litcofsky, ... Open Forum Infectious Diseases 4 (suppl_1), S389-S390, 2017 | 2 | 2017 |
| Designed bacterial compositions and uses thereof A Martinez, EJ O'brien, SL Simmons, D Cook, MR Henn, ... US Patent App. 17/780,831, 2023 | | 2023 |
Parul TomarMax Planck Institute of Immunbiology and EpigeneticsПодтвержден адрес электронной почты в домене ie-freiburg.mpg.de
